
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Immunoglobulin,Human Immunoglobulin
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : CSI Pharmacy
Deal Size : Undisclosed
Deal Type : Agreement
CSI Pharmacy Announces Limited Distribution Agreement for Gammaplex
Details : Under the agreement, CSI Pharmacy will get access for limited distribution rights to BPL's immune globulin product Gammaplex® (human immunoglobulin). Immune globulin products contain human antibodies, derived primarily from donated human plasma.
Product Name : Gammaplex
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Immunoglobulin,Human Immunoglobulin
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : CSI Pharmacy
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Coagulation Factor X (Human),Coagulation Factor X
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BPL Receives Orphan Drug Marketing Authorization for Coagadex® in Mexico
Details : Coagadex® is the first and only treatment specifically for Hereditary Factor X Deficiency, a very rare inherited clotting disorder that causes problems with blood clotting due to not having enough Factor X in the blood.
Product Name : Coagadex
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Coagulation Factor X (Human),Coagulation Factor X
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HRIG
Therapeutic Area : Undisclosed
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects
Details : HRIG is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 29, 2017
Lead Product(s) : HRIG
Therapeutic Area : Undisclosed
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor IX is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia B.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 13, 2014
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor IX is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia B.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 13, 2014
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor IX is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia B.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 26, 2014
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor IX is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia B.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 26, 2014
Lead Product(s) : Factor IX
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Optivate Human Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Optivate Human Coagulation Factor VIII is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 26, 2014
Lead Product(s) : Optivate Human Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Optivate Human Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Optivate Human Coagulation Factor VIII is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of von Willebrand Diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 26, 2014
Lead Product(s) : Optivate Human Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Human Normal Immunoglobulin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®
Details : Human Normal Immunoglobulin is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Primary Immunodeficiency Diseases.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 23, 2014
Lead Product(s) : Human Normal Immunoglobulin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
